Astrazeneca Plc (AZN) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Astrazeneca Plc  (NASDAQ: AZN)

Astrazeneca Plc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Astrazeneca Plc in the fourth quarter 2025?
Astrazeneca Plc achieved a return on average equity (ROE) of 26.56 % in its fourth quarter 2025, this is above AZN's average return on equity of 13.22%.
Astrazeneca Plcs equity during the 12 months ending in the fourth quarter 2025 are valued at $47 billion

ROE has advanced compared to 20.73% in the third quarter 2025, due to net income growth.

Within the Major Pharmaceutical Preparations industry 31 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 0 to 895.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change 19.2 % 19.2 % 13.16 % 19.2 % -
Y / Y Net Income Change 45.33 % - 26.97 % - 18.12 %
Net Income (TTM) in Millions 12,681 9,489 9,489 8,969 8,969
Return On Equity (TTM) 26.56 % 20.73 % 21.66 % 21.1 % 22.12 %
AZN's Total Ranking # 895 # 0 # # #
Equity (TTM) in Millions 48,719 48,719 44,810 48,719 40,871
Seq. Equity Change 0 % 8.72 % -8.02 % 19.2 % 0 %
Seq. Net Income Change - - - - -

Back to AZN Management Effectiveness >> AZN's 5 Years Annual ROE >> Compare AZN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 32
Sector # 75
Overall # 895

Return On Equity Statistics
High Average Low
21 %
13.22 %
0.29 %
(Dec 31 2025)   (Dec 31 2021)



  News about Astrazeneca Plc Return on Equity ROE

AstraZeneca Under Scrutiny Investor Action and Strong Financial Performance Amid Legal Challenges

AstraZeneca PLC, a major global player in the pharmaceutical industry, is currently navigating a critical juncture as it faces a securities class action lawsuit. This comes amid a backdrop of positive financial performance, raising questions about the company s standing in the market and the implications of the legal proceedings. Investor Action and Legal Notice Rosen Law Firm, a prominent investor rights law firm, has issued a reminder to shareholders of AstraZeneca regarding an impending deadline related to a securities class action lawsuit. Investors who purchased AstraZeneca securities between February 23, 2022, and December 17, 2024, are urged to secure legal counsel before the lead plaintiff deadline of February 21, 2025. The law firm’s proactive communication underscores the seriousness of the allegations and the necessity for affected investors to act promptly.



AZN Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 48,719 40,871 39,166 37,058 39,287
Y / Y Equity Change 19.2 % 4.35 % 5.69 % -5.67 % 151.23 %
Net Income in Millions 10,233 7,041 5,961 3,293 115
Y / Y Net Income Change 45.33 % 18.12 % 81.02 % 2763.48 % -96.34 %
Return On Equity 21 % 17.23 % 15.22 % 8.89 % 0.29 %

Back to AZN Management Effectiveness >> AZN's 5 Years Annual ROE >> Compare AZN ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 21 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
AZN's' Return on Equity at Yahoo Finance
AZN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for AZN's Competitors
Subscribers only: Roe for Astrazeneca Plc's Suppliers
Subscribers only: Return On Equity for AZN's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE
3m Company  71.32 %
Entera Bio Ltd   70.43 %
Aurinia Pharmaceuticals Inc   70.37 %
Idexx Laboratories Inc  69.78 %
Alnylam Pharmaceuticals Inc   69.25 %
Enlivex Therapeutics Ltd  63.85 %
Dariohealth Corp   59.48 %
Nrc Health  58.51 %
Zoetis Inc   56.31 %
Alpha Tau Medical Ltd  55.29 %
Transmedics Group Inc   53.88 %
Pulmatrix Inc   53.50 %
Abeona Therapeutics Inc   53.18 %
Novo Nordisk A  52.79 %
Medinotec Inc   52.76 %
Concentra Group Holdings Parent Inc   47.62 %
Theravance Biopharma inc   46.03 %
Galmed Pharmaceuticals Ltd   43.72 %
Acadia Pharmaceuticals Inc   41.90 %
Arrowhead Pharmaceuticals Inc   41.16 %
Gilead Sciences Inc   41.14 %
Tenet Healthcare Corp  40.89 %
Agilent Technologies inc   40.80 %
Bristol myers Squibb Company  39.17 %
Gsk Plc  38.67 %
Hutchmed china Limited  36.98 %
Oramed Pharmaceuticals Inc  36.81 %
Solventum Corporation  36.74 %
Newgenivf Group Limited  36.53 %
Merck and Co Inc   36.16 %

Date modified: 2026-07-07T09:23:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.